US Pharma MarketingLack of biosimilar development could cost billions in lost savings, report warns
The findings underscore one of the hard truths of the US drug market: Cheaper options can only reach patients if they’re made. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
A trade group representing generics and biosimilars is warning that the lack of product development could imperil billions of dollars in potential savings.
The new report released Thursday by the Association ...
Source: Endpoints News